Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

|Videos|June 13, 2022

Dr. Lotan on the iodine-based contrast media shortage

Author(s)Urology Times staff

“For patients who are several years out from treatment for bladder cancer or kidney cancer, I don't think [the shortage is] going to have a clinical impact. For more acute settings, I have tried to rely a little bit more on MR urograms and ultrasound,” says Yair Lotan, MD.

In this interview, Yair Lotan, MD, is a professor of urology, chief of Urologic Oncology, the Jane and John Justin Distinguished Chair in Urology, in honor of Claus G. Roehrborn, MD, and vice chair of clinical affairs at the University of Texas Southwestern Medical Center in Dallas.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Kathryn Gessner, MD, PhD, on the challenges of selecting patients for bladder preservation

ByKate Gessner, MD, PhD

July 20th 2026

Richard Schlussel, MD, highlights emerging technologies in pediatric urology

ByRichard N. Schlussel, MD

July 17th 2026

Team-based AE protocols improve consistency with the gemcitabine intravesical therapy system

ByElizabeth Mobley, MD

July 16th 2026

Practical tips for AE management with the gemcitabine intravesical system

ByElizabeth Mobley, MD

July 16th 2026

Elizabeth Mobley, MD, on setting expectations and hydration protocols for the gemcitabine intravesical system

ByElizabeth Mobley, MD

July 16th 2026

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

Study to assess adaptive-dosed 177Lu-DOTA-HYNIC-panPSMA in mHSPC

Practical tips for AE management with the gemcitabine intravesical system

Team-based AE protocols improve consistency with the gemcitabine intravesical therapy system

First-in-human bladder transplant demonstrates sustained function at 6 months

Department of Defense announces annual testosterone deficiency screening for service members